IGF-1 DES

Preclinical only Muscle & Bone Health 3 sources

IGF-1 DES (DES(1-3)IGF-1) is a truncated variant of Insulin-like Growth Factor 1 that lacks the first three amino acids at the N-terminus. This structural modification prevents it from binding to IGF-binding proteins (IGFBPs), resulting in a highly potent, fast-acting peptide. Research primarily focuses on its ability to stimulate cellular hyperplasia and localized tissue repair, particularly in skeletal muscle and gut mucosa.

01Dosing reference

Amount

20-50 mcg per day (often split bilaterally into target muscles)

Frequency

Pre-workout or immediately post-workout on training days

Cycle

4 weeks on, followed by 4 weeks off

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Unbound Receptor Activation

Because it lacks the first three amino acids, IGF-1 DES cannot bind to IGF-binding proteins (IGFBPs), allowing it to freely and rapidly bind directly to the IGF-1 receptor on cell surfaces.

Cellular Hyperplasia

Once bound, it stimulates the proliferation and differentiation of cells, particularly satellite cells in muscle tissue, leading to the creation of new muscle fibers rather than just enlarging existing ones.

Nutrient Partitioning and Repair

It enhances the rapid uptake of amino acids and glucose into localized cells, promoting immediate tissue repair, growth, and recovery in the targeted area.

03Human evidence

Lack of dedicated human clinical trials for IGF-1 DES.

While full-length recombinant human IGF-1 (rhIGF-1) has been studied in humans for growth disorders, the DES(1-3) variant lacks formal human clinical trials, leaving its specific effects, safety, and efficacy in humans largely extrapolated from animal models and anecdotal reports.

04Preclinical evidence

Significantly enhanced potency compared to standard IGF-1.

In vitro and animal studies demonstrate that DES(1-3)IGF-1 is up to 10 times more potent than standard IGF-1 at stimulating hypertrophy and cellular growth due to its inability to be deactivated by IGFBPs.

Improved gut mucosal healing and tissue repair.

Animal models of inflammatory bowel disease have shown that IGF-1 DES significantly improves gut tissue repair, increases mucosal mass, and reduces inflammation more effectively than standard IGF-1.

05What is known vs. unknown

Reasonably established

Lacks the first three amino acids of standard IGF-1, preventing it from binding to deactivating IGF-binding proteins (IGFBPs).
Exhibits a very short half-life of approximately 20 to 30 minutes, making its effects highly localized and rapid.
Promotes cellular hyperplasia (the creation of new cells) in addition to hypertrophy (the enlargement of existing cells).
Demonstrates significantly higher potency than standard IGF-1 in preclinical models of tissue repair and muscle growth.

Unknowns & limits

Long-term safety and potential risks of systemic exposure are not well documented in human subjects.
The exact optimal dosing protocols for human therapeutic use remain unestablished due to a lack of clinical trials.
Potential risks regarding cellular proliferation and the acceleration of existing cancer cell growth require further investigation.

06Safety & regulatory context

Regulatory statusIGF-1 DES is an experimental research chemical and is not approved by the FDA for human use. Due to its potent ability to stimulate cellular growth and proliferation, there are theoretical concerns regarding its potential to accelerate the growth of existing tumors or cancer cells. Known side effects in research settings include hypoglycemia (low blood sugar), localized swelling or pain at the injection site, and potential joint or nerve pain. It is strictly regulated in sports and is listed as a banned substance by the World Anti-Doping Agency (WADA) under the category of growth factors.

07Compared with IGF-1 LR3

IGF-1 DES vs. IGF-1 LR3

Key difference

IGF-1 DES has a very short half-life (20-30 minutes) and is used for rapid, localized effects, whereas IGF-1 LR3 has a much longer half-life (20-30 hours) and provides sustained, systemic effects.

When researchers discuss each

Researchers discuss IGF-1 DES when focusing on immediate, localized tissue repair and site-specific growth (often post-injury or post-training), while IGF-1 LR3 is preferred for overall systemic anabolic effects and prolonged receptor activation.

08Glossary

Hyperplasia

The enlargement of an organ or tissue caused by an increase in the reproduction rate of its cells, often resulting in the creation of new muscle fibers.

IGF-Binding Proteins (IGFBPs)

Proteins that bind to IGF-1 in the body, regulating its availability and extending its half-life but reducing its immediate potency.

Half-life

The time required for the concentration of a substance in the body to reduce by half, which dictates how long its effects last.

09Knowledge check

Q1Why is IGF-1 DES considered more potent than standard IGF-1 in short-term applications?

Q2What is the primary difference in the mechanism of action between IGF-1 DES and IGF-1 LR3?

Q3Which statement best reflects the dossier’s level of evidence for IGF-1 DES effects in humans?

Q4According to the dossier, researchers typically choose IGF-1 DES instead of IGF-1 LR3 when they are looking for which research context?

Q5Which statement aligns with the dossier’s safety and regulatory context for IGF-1 DES?

10Sources

More in Muscle & Bone Health

See all

IGF-1 LR3

Muscle & Bone Health

Early human

IGF-1 LR3 is a synthetic, modified version of Insulin-like Growth Factor-1 with an extended half-life and increased potency. Research highlights its ability to promote muscle cell hyperplasia (growth of new muscle cells), enhance protein synthesis, and improve recovery by resisting deactivation by IGF-binding proteins.

20-50 mcg per day

GDF-8 Myostatin Inhibitor

Muscle & Bone Health

Early human

GDF-8 (Growth Differentiation Factor 8), commonly known as myostatin, is a protein that naturally inhibits muscle growth. Myostatin inhibitors are compounds designed to block this protein, thereby promoting significant muscle hypertrophy and preventing muscle wasting in various research models.

1 mg - 3 mg (highly variable depending on specific peptide/antibody)

ACE-031

Muscle & Bone Health

Early human

ACE-031 is an investigational protein therapeutic designed to build muscle and increase strength by inhibiting signaling through the activin receptor type IIB (ActRIIB). Research primarily focused on its potential to treat muscle-wasting diseases like Duchenne muscular dystrophy, though clinical trials were halted due to safety concerns involving bleeding.

1-3 mg/kg (in clinical trial settings)

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.